期刊文献+

普奈洛尔治疗肝硬化腹水及其对肾素、血管紧张素和醛固酮系统的影响 被引量:3

原文传递
导出
摘要 目的探讨普萘洛尔治疗肝硬化腹水疗效及其可能机制。方法选择70例乙肝后肝硬化并腹水患者,在护肝、利尿等治疗基础上,随机分成2组,每组各35例,普萘洛尔组(治疗组)与对照组,对比观察治疗前后2组尿量变化、腹水消退情况及血浆肾素活性(PRA)、血管紧张素Ⅱ(AⅡ)、醛固酮(ALD)水平。结果治疗组血浆PRA、AⅡ、ALD水平明显下降,与同组治疗前及对照组治疗前后比较,差异有统计学意义(P〈0.05)。治疗组24h尿量较对照组有明显增加(P〈0.05),腹水治疗有效率差异有统计学意义(P〈0.05)。结论在常规治疗基础上加用普萘洛尔治疗肝硬化腹水,能有效促进腹水消退,缩短腹水治疗时间。同时可抑制肾素-血管紧张素-醛固酮系统(RAAS)活性,避免因利尿诱发RAAS过度激活。
出处 《中国医师杂志》 CAS 2009年第6期854-855,共2页 Journal of Chinese Physician
  • 相关文献

参考文献9

  • 1中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14013
  • 2贾俊亚,丁国华.肾脏中肾素-血管紧张素系统的生理和病理生理作用[J].生理科学进展,2008,39(1):71-74. 被引量:18
  • 3Crowley SD, Gurley SB, Oliverio MI, et al. Distinct roles for the kidney And systemic tissues in blood pressure regulation by thyrenin-angiotensin system. Clin Invest ,2005,115 : 1092-1099.
  • 4Schrier RW, Gurevich AK, Cadnapaphornchai MA. Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis. Semin Nephrol,2001,21 (2) : 157-172.
  • 5Blendis L, Wong F. The hyperdynamic circulation in cirrhosis:an overview. Phannacol Ther,2001,89 ( 3 ) :221-231.
  • 6张晶,魏红山,李定国.血管紧张素Ⅱ与肝硬化[J].中华消化杂志,2002,22(6):363-365. 被引量:18
  • 7白艳丽,杨玉珍.肾素、血管紧张素Ⅱ及抗利尿激素与肝硬化腹水形成的关系[J].胃肠病学和肝病学杂志,2007,16(1):76-77. 被引量:17
  • 8Helmy A, Jalan R, Newhy DE, et al. Role of angiotensin Ⅱ in regulation of basal and sympathetically stimulated vascular tone inearly and advanced cirrhosis. Gastroenterology, 2000, 118:565-575.
  • 9Ackermann D, Mordasini D, Cheval L, et al. Sodiumretention and ascites formation in a cholestatic mice model: role of aldosterone and mineralocorticoid receptor. Hepatology ,2007,46 ( 1 ) : 173-179.

二级参考文献13

  • 1Molier S, Bendtsen F, Henriksen JH. Determinants of the renin-angiotensin-aldosterone system in cirrhosis with special emphasis on the central blood volume [J]. Scand J of Gastroenterol, 2006,41 (4): 451-458.
  • 2Navar LG, Nishiyama A. Why are angiotensin concentrations so high in the kidney? Curr Opin Nephrol Hypertens, 2004, 13 : 107 - 115.
  • 3Crowley SD, Gurley SB, Oliverio MI, et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest, 2005, 115 : 1092 - 1099.
  • 4Lasaitiene D, Chen Y, Adams MA, et al. Further insights into the role of angiotensin II in kidney development. Clin Physiol Funct Imaging, 2006, 26 : 197 -204.
  • 5Nguyen G. The (pro) renin receptor: Pathophysiological roles in cardiovascular and renal pathology. Curr Opin Nephrol Hypertens, 2007, 16 : 129- 133.
  • 6Chen J, Chen JK, Neilson EG, et al. Role of EGF receptor activation in angiotensin II-induced renal epithelial cell hypertrophy. J Am Soc Nephrol, 2006, 17 : 1615 - 1623.
  • 7Kohlstedt RP, Brandis W, Muller-Esterl R, et al. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res, 2004, 94 : 60 - 67.
  • 8Ye M, Wysocki J, William J, et al. Glomerular localization and expression of angiotensin converting enzyme 2 and angiotensin converting enzyme: Implications for albuminuria in Diabetes. J Am Soc Nephrol, 2006, 17 : 3067 - 3075.
  • 9吕小平,詹灵凌,姜海行.肝硬化患者血浆P物质、内皮素和抗利尿激素水平变化与门脉高压的关系[J].广西医科大学学报,2000,17(2):195-196. 被引量:4
  • 10魏红山,李定国,陆汉明,展玉涛,王志荣,黄新,潘勤,徐芹芳.血管紧张素Ⅱ受体阻断剂抗肝纤维化的实验研究[J].中华肝脏病杂志,2000,8(5):302-304. 被引量:31

共引文献14051

同被引文献15

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部